Arvinas (NASDAQ:ARVN) Reaches New 52-Week Low – Time to Sell?

Arvinas, Inc. (NASDAQ:ARVN) shares hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $15.53 and last traded at $16.02, with a volume of 42764 shares. The stock had previously closed at $16.23.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Wedbush reissued an “outperform” rating and set a $57.00 price objective on shares of Arvinas in a research report on Tuesday, February 11th. Barclays dropped their price target on shares of Arvinas from $48.00 to $32.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. Stephens began coverage on shares of Arvinas in a research report on Monday, November 18th. They set an “overweight” rating and a $55.00 price target for the company. Oppenheimer raised their price objective on shares of Arvinas from $40.00 to $45.00 and gave the company an “outperform” rating in a research note on Wednesday, February 12th. Finally, Guggenheim reissued a “buy” rating and issued a $57.00 price objective on shares of Arvinas in a research note on Wednesday, February 12th. Twelve analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Arvinas presently has a consensus rating of “Buy” and an average target price of $60.00.

Arvinas Price Performance

The business’s 50 day moving average is $18.36 and its 200-day moving average is $22.66. The company has a market cap of $1.10 billion, a PE ratio of -5.77 and a beta of 1.88.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period in the prior year, the company earned ($2.53) earnings per share. As a group, sell-side analysts predict that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Insider Transactions at Arvinas

In other news, insider Ian Taylor sold 9,020 shares of Arvinas stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.71, for a total value of $150,724.20. Following the transaction, the insider now directly owns 159,121 shares of the company’s stock, valued at $2,658,911.91. The trade was a 5.36 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO John G. Houston sold 31,338 shares of the business’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.72, for a total transaction of $523,971.36. Following the completion of the transaction, the chief executive officer now directly owns 1,157,480 shares in the company, valued at $19,353,065.60. This represents a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 41,572 shares of company stock worth $695,030. 5.23% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Arvinas

Several institutional investors have recently bought and sold shares of ARVN. GF Fund Management CO. LTD. acquired a new position in shares of Arvinas during the 4th quarter worth $28,000. KBC Group NV grew its stake in shares of Arvinas by 77.0% during the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after purchasing an additional 1,255 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Arvinas by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock worth $61,000 after buying an additional 440 shares in the last quarter. Quantbot Technologies LP boosted its position in shares of Arvinas by 147.3% in the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock worth $108,000 after buying an additional 2,601 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Arvinas in the 4th quarter worth about $171,000. 95.19% of the stock is owned by institutional investors and hedge funds.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.